商业保险患者接受晚期前列腺癌当代治疗的自付费用负担
研究纳入2007至2019年OptumLabs数据库中13,409例接受晚期前列腺癌治疗的商业保险男性,比较三种治疗方式第一年治疗相关自付费用。新型激素治疗自付费用显著高于雄激素剥夺单药治疗,调整后差值为2,581美元(95%CI:1,923-3,240美元)。
要点
- 新型激素治疗第一年治疗相关自付费用均值4,236美元,雄激素剥夺单药治疗为165美元。
- 调整后新型激素治疗自付费用较雄激素剥夺单药治疗高2,581美元(95%CI:1,923-3,240美元)。
- 年龄65-74岁、黑人种族、较低合并症评分和较低家庭收入与更高治疗相关自付费用相关(P<.05)。
核心结论
- 接受新型激素治疗的晚期前列腺癌患者治疗相关自付费用显著更高。
- 数据支持将治疗相关经济毒性纳入晚期前列腺癌共享决策,并关注尤其易受经济毒性影响的患者亚组。
研究设计与样本
- 研究识别2007年至2019年在OptumLabs Data Warehouse®内接受晚期前列腺癌治疗的所有商业保险男性。
- 患者分为3个治疗组:雄激素剥夺单药治疗、新型激素治疗和非雄激素系统性治疗。
- 主要结局为治疗第一年的自付费用,采用多变量回归模型评估治疗和患者变量与自付费用的关联。
- 所有费用使用消费者价格指数调整为2019年美元。
主要发现
- 队列共13,409例男性,其中81%(n=10,926)接受雄激素剥夺单药治疗,6%(n=832)接受新型激素治疗,12%(n=1,651)接受非雄激素系统性治疗。
- 第一年治疗相关自付费用均值:雄激素剥夺单药治疗165美元,新型激素治疗4,236美元,非雄激素系统性治疗994美元。
- 调整后年治疗相关自付费用差值:新型激素治疗较雄激素剥夺单药治疗高2,581美元(95%CI:1,923-3,240美元),非雄激素系统性治疗较雄激素剥夺单药治疗高752美元(95%CI:600-903美元)。
- 与更高治疗相关自付费用相关的患者特征(P<.05)包括:年龄较大(65-74岁)、黑人种族、较低合并症评分和较低家庭收入。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Out-of-pocket costs represent an important component of financial toxicity and may impact patients' receipt of care. Herein, we evaluated patient-level factors associated with out-of-pocket costs for contemporary advanced prostate cancer treatment options. MATERIALS AND METHODS: We identified all commercially insured men receiving treatment for advanced prostate cancer between 2007 and 2019 within the OptumLabs Data Warehouse®. Patients were categorized into 3 treatment groups: androgen deprivation monotherapy, novel hormonal therapy, and nonandrogen systemic therapy. The primary outcome was out-of-pocket costs in the first year of treatment. The associations of treatment and patient variables with out-of-pocket costs were assessed using multivariable regression models. All costs were adjusted to reflect 2019 U.S. dollars using the Consumer Price Index. RESULTS: In a cohort of 13,409 men 81% (n = 10,926) received androgen deprivation monotherapy, 6% (n = 832) novel hormonal therapy, and 12% (n = 1,651) nonandrogen systemic therapy. Mean treatment-related out-of-pocket costs in the first year were $165, $4,236, and $994 for androgen deprivation monotherapy, novel hormonal therapy, and nonandrogen systemic therapy, respectively. The adjusted difference in annual treatment-related out-of-pocket costs for novel hormonal therapy and nonandrogen systemic therapy were $2,581 (95% CI: $1,923-$3,240) and $752 (95% CI: $600-$903) higher than androgen deprivation monotherapy, respectively. Patient characteristics associated (P < .05) with higher treatment-related out-of-pocket costs included older age (65-74 years), Black race, lower comorbidity scores, and lower household income. CONCLUSIONS: Patients receiving novel hormonal therapy for advanced prostate cancer had substantially higher treatment-related out-of-pocket costs. In addition to raising awareness among prescribers, these data support the inclusion of treatment associated financial toxicity in shared decision making for advanced prostate cancer and call attention to subgroups of patients particularly vulnerable to financial toxicity.
引用
- Joyce DD, Sharma V, Jiang DH, et al. Out-of-Pocket Cost Burden Associated With Contemporary Management of Advanced Prostate Cancer Among Commercially Insured Patients. J Urol. 2022. PMID: 36094864. doi:10.1097/JU.0000000000002856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。